MX2023003875A - Formulacion de una vacuna peptidica. - Google Patents

Formulacion de una vacuna peptidica.

Info

Publication number
MX2023003875A
MX2023003875A MX2023003875A MX2023003875A MX2023003875A MX 2023003875 A MX2023003875 A MX 2023003875A MX 2023003875 A MX2023003875 A MX 2023003875A MX 2023003875 A MX2023003875 A MX 2023003875A MX 2023003875 A MX2023003875 A MX 2023003875A
Authority
MX
Mexico
Prior art keywords
formulation
pharmaceutical composition
composition
peptide vaccine
reconstitution
Prior art date
Application number
MX2023003875A
Other languages
English (en)
Inventor
Gwenn Eveline Mulder
Original Assignee
Isa Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V filed Critical Isa Pharmaceuticals B V
Publication of MX2023003875A publication Critical patent/MX2023003875A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La invención se relaciona a una composición de reconstitución novedosa, una composición farmacéutica y un kit de partes que comprende dicha composición de reconstitución. La invención además se relaciona a un método de tratamiento utilizando dicha composición farmacéutica y/o la composición farmacéutica para su utilización como medicamento. Además, se proporciona un método para reconstituir péptidos desecados y un método para preparar una composición farmacéutica utilizando la composición de reconstitución de la invención.
MX2023003875A 2016-06-20 2018-12-14 Formulacion de una vacuna peptidica. MX2023003875A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16175215 2016-06-20

Publications (1)

Publication Number Publication Date
MX2023003875A true MX2023003875A (es) 2023-04-18

Family

ID=56148213

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015749A MX2018015749A (es) 2016-06-20 2017-06-19 Formulacion de una vacuna peptidica.
MX2023003875A MX2023003875A (es) 2016-06-20 2018-12-14 Formulacion de una vacuna peptidica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015749A MX2018015749A (es) 2016-06-20 2017-06-19 Formulacion de una vacuna peptidica.

Country Status (14)

Country Link
US (3) US10702598B2 (es)
EP (2) EP3471758A1 (es)
JP (2) JP7115803B2 (es)
KR (2) KR20190020098A (es)
CN (2) CN109641039B (es)
AU (2) AU2017281389B2 (es)
CA (1) CA3027459A1 (es)
EA (1) EA201990071A1 (es)
IL (2) IL291537B2 (es)
MX (2) MX2018015749A (es)
MY (1) MY189551A (es)
SG (1) SG11201811442UA (es)
WO (1) WO2017220463A1 (es)
ZA (1) ZA202100578B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659748B (zh) * 2014-06-26 2021-08-31 洛克菲勒大学 不动杆菌属溶素
JP7362249B2 (ja) * 2015-03-20 2023-10-17 チルドレンズ ナショナル メディカル センター ナイーブｔ細胞集団からのウイルスまたは他の抗原に特異的なｔ細胞の生成
TW202333779A (zh) 2017-05-08 2023-09-01 美商磨石生物公司 阿爾法病毒新抗原載體
CA3088837A1 (en) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
KR20210013105A (ko) * 2018-05-23 2021-02-03 그릿스톤 온콜로지, 인코포레이티드 공유 항원
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
CN114901676A (zh) * 2019-08-15 2022-08-12 国家生物技术研究所公司 递送肽及其使用方法
WO2021247534A2 (en) * 2020-06-01 2021-12-09 The Broad Institute, Inc. Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
CN117730247A (zh) 2021-07-12 2024-03-19 Isa制药有限公司 复杂混合物中改善的物质定量
CN113842455B (zh) * 2021-08-27 2022-05-13 北京康乐卫士生物技术股份有限公司 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗
KR102545000B1 (ko) * 2021-10-20 2023-06-16 전옥님 그래핀을 이용한 전자파 차폐 시트
WO2023143445A1 (zh) * 2022-01-25 2023-08-03 厦门大学 用于治疗hbv感染及相关疾病的表位肽及抗体
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003753A1 (en) 1991-08-26 1993-03-04 The Scripps Research Institute Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
US20110097352A9 (en) 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
DK0726758T3 (da) 1993-08-02 2003-03-03 Scripps Research Inst Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
AU765822B2 (en) 1998-05-23 2003-10-02 Leiden University Medical Center CD40 binding molecules and CTL peptides for treating tumors
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE10059631A1 (de) 2000-12-01 2002-07-18 Medigene Ag T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie
EP1355925A2 (en) * 2000-12-08 2003-10-29 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
ES2724121T3 (es) 2000-12-08 2019-09-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
EP1479761A1 (en) 2003-05-21 2004-11-24 PrimaGen Holding B.V. New enterovirus, vaccines, medicaments and diagnostic kits
CN104826116A (zh) * 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
KR20080030024A (ko) * 2005-06-17 2008-04-03 호스피라 오스트레일리아 피티와이 리미티드 도세탁셀의 약제학적 액상제제
EP3533461A3 (en) 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
EP2155780B1 (en) 2007-05-31 2013-02-27 Academisch Ziekenhuis Leiden h.o.d.n. LUMC P53 peptide vaccine
AU2008257792B2 (en) 2007-05-31 2013-08-29 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
CA2688589A1 (en) * 2007-05-31 2008-12-31 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal hpv peptide vaccination
KR20090125629A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
KR20090125628A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
US8697644B2 (en) 2011-03-10 2014-04-15 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013006050A1 (en) 2011-07-06 2013-01-10 Isa Pharmaceuticals B.V. Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
CA2874923C (en) * 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
KR20230145545A (ko) 2013-04-07 2023-10-17 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
KR102569204B1 (ko) 2014-06-02 2023-08-22 아이에스에이 파마슈티컬즈 비.브이. B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp)

Also Published As

Publication number Publication date
CN117018170A (zh) 2023-11-10
US11426458B2 (en) 2022-08-30
US10702598B2 (en) 2020-07-07
ZA202100578B (en) 2023-03-29
JP2022141878A (ja) 2022-09-29
US20200297835A1 (en) 2020-09-24
WO2017220463A1 (en) 2017-12-28
MY189551A (en) 2022-02-16
SG11201811442UA (en) 2019-01-30
CN109641039B (zh) 2023-08-04
IL263846B (en) 2022-04-01
AU2024202005A1 (en) 2024-04-18
JP2019525950A (ja) 2019-09-12
CA3027459A1 (en) 2017-12-28
US20230233658A1 (en) 2023-07-27
IL263846A (en) 2019-01-31
IL291537B2 (en) 2023-11-01
KR20190020098A (ko) 2019-02-27
AU2017281389B2 (en) 2024-02-22
JP7115803B2 (ja) 2022-08-09
EP3471758A1 (en) 2019-04-24
CN109641039A (zh) 2019-04-16
EP3552623A1 (en) 2019-10-16
KR20230030032A (ko) 2023-03-03
AU2017281389A1 (en) 2019-02-07
MX2018015749A (es) 2019-06-17
IL291537A (en) 2022-05-01
US20190231863A1 (en) 2019-08-01
IL291537B1 (en) 2023-07-01
EA201990071A1 (ru) 2019-06-28

Similar Documents

Publication Publication Date Title
MX2023003875A (es) Formulacion de una vacuna peptidica.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
PH12017500450A1 (en) Flavivirus virus like particle
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
NZ730708A (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
CR20160495A (es) Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
SG10201900933YA (en) Koc1-derived peptide and vaccine including same
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
SG10201900879PA (en) Cdca1-derived peptide and vaccine containing same
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
WO2016091890A8 (en) Meningitidis vaccines comprising subtilinases
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения